1 completed, 1 terminated, 1 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Lung Cancer Group Cologne: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGFR Inhibitor in FGFR Dysregulated Cancer ERDAFITINIB - Lung Cancer, NSCLC | Phase 2 | Terminated | Lung Cancer Group Cologne | 22 | 2019-03-25 | 2023-06-09 |
| BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Nivolumab, Ipilimumab - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Completed | Lung Cancer Group Cologne | 90 | 2017-04-13 | 2024-01-17 |
| Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) erlotinib, FDG-/FLT-PET - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Lung Cancer Group Cologne | 40 | 2007-10-01 | 2009-09-17 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Erlotinib Hydrochloride (1) · Ipilimumab (1) · Nivolumab (1) · erdafitinib (1)
Germany (3)
Juergen Wolf, Prof., Dr. (1) · Lucia Nogova, MD (1)
2005 (1), 2016 (1), 2018 (1)